Title |
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
|
---|---|
Published in |
Memórias do Instituto Oswaldo Cruz, August 2014
|
DOI | 10.1590/0074-0276140156 |
Pubmed ID | |
Authors |
Bianca Zingales, Michael A Miles, Carolina B Moraes, Alejandro Luquetti, Felipe Guhl, Alejandro G Schijman, Isabela Ribeiro |
Abstract |
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Argentina | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | <1% |
India | 1 | <1% |
Argentina | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 198 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 32 | 16% |
Student > Master | 31 | 15% |
Student > Ph. D. Student | 28 | 14% |
Student > Doctoral Student | 20 | 10% |
Student > Bachelor | 17 | 8% |
Other | 33 | 16% |
Unknown | 41 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 40 | 20% |
Agricultural and Biological Sciences | 30 | 15% |
Medicine and Dentistry | 21 | 10% |
Chemistry | 21 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 16 | 8% |
Other | 25 | 12% |
Unknown | 49 | 24% |